Neurocentria

Neurocentria is a private, late-stage biotech pioneering a new class of therapies based on the novel mechanism of elevating intracellular magnesium at synapses to promote synaptogenesis and enhance synaptic function. Its lead drug candidate, NRCT-101SR, is in Phase 2b/3 trials for ADHD, depression, and Alzheimer's disease, with early clinical data showing rapid mood improvement and cognitive benefits. The company also has a revenue-generating nutraceutical arm, Magtein®, which serves as a commercial foundation and proof-of-concept for its core science.

Novel small molecule platform focused on selectively elevating intracellular magnesium at synaptic terminals to promote synaptogenesis, enhance synaptic plasticity, and improve cognitive and emotional function.

Neurocentria competes in crowded markets dominated by established drugs, but its synaptic plasticity mechanism is distinct from standard serotonin/norepinephrine/dopamine reuptake inhibitors or acetylcholinesterase inhibitors. It faces competition from other novel neuroplasticity and disease-modifying approaches in development from larger, better-funded biopharma companies.